Rank | INN | Total Licensed Formulations | WHO (EML) | Pakistan (EML) | India (NF) | AwaRe Class |
---|---|---|---|---|---|---|
1 | Azithromycin | 116 | Yes | Yes | Yes | Watch |
Cephradine-cilastatin | 116 | Access | ||||
2 | Cefuroxime | 99 | Yes | Yes | Watch | |
3 | Cefixime | 97 | Yes | Yes | Yes | Watch |
4 | Ciprofloxacin | 96 | Yes | Yes | Yes | Watch |
5 | Amoxicillin | 84 | Yes | Yes | Yes | Access |
6 | Flucloxacillin | 78 | Access | |||
7 | Nitazoxanide | 64 | N/A | |||
Cefpodoxime | 64 | Watch | ||||
8 | Metronidazole | 60 | Yes | Yes | Yes | Access |
9 | Erythromycin | 55 | Yes | Yes | Watch | |
10 | Levofloxacin | 37 | Yes | Yes | Watch | |
Cotrimoxazole | 37 | Yes | Yes | Yes | Access |
Abbreviations: AWaRe, Access, Watch, and Reserve classification; EML, Essential Medicines List; INN, international nonproprietary names of pharmaceuticals; N/A, not applicable or not classified; NF, National Formulary; WHO, World Health Organization.